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Background: TP53 mutations are among the most common mutations found in lung
cancers, identified as an independent prognostic factor in many types of cancers. The
purpose of this study was to investigate the frequency and prognostic impact of TP53
mutations in never-smokers and in different histological subtypes of lung cancer.
Methods: We analyzed tumor tissue from 394 non-small cell carcinomas including
adenocarcinomas (n= 229), squamous cell carcinomas (n= 112), large cell carcinomas
(n = 30), and others (n = 23) for mutations in TP53 by the use of Sanger sequencing
(n = 394) and next generation sequencing (n = 100).
Results: TP53 mutations were identified in 47.2% of the samples, with the highest
frequency (65%) of mutations among squamous cell carcinomas. Among never-
smokers, 36% carried a TP53 mutation, identified as a significant independent negative
prognostic factor in this subgroup. For large cell carcinomas, a significantly prolonged
progression free survival was found for those carrying a TP53 mutation. In addition, the
frequency of frameshift mutations was doubled in squamous cell carcinomas (20.3%)
compared to adenocarcinomas (9.1%).
Conclusion: TP53 mutation patterns differ between the histological subgroups of lung
cancers, and are also influenced by smoking history. This indicates that the histological
subtypes in lung cancer are genetically different, and that smoking-induced TP53
mutations may have a different biological impact than TP53 mutations occurring in
never-smokers.
Keywords: adenocarcinomas, squamous cell carcinomas, large cell carcinomas, TP53, never-smoker, mutation
spectrum, progression free survival
Abbreviations: AC, adenocarcinomas; DBM, DNA binding motif; LCC, large cell carcinomas; non-DBM, non-DNA binding
motif; NSCLC, non-small cell lung cancers; PFS, progression free survival; SCC, squamous cell carcinomas; SCLC, small cell
lung cancers; WT, wild-type.
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INTRODUCTION
Lung cancer is one of the most common types of cancers, and
due to its aggressiveness, this disease is also positioned as the
most deadly cancer disease worldwide (Ferlay et al., 2015). Lung
cancers can be divided into small-cell lung carcinomas (SCLC)
and non-small cell lung carcinomas (NSCLC), consisting of
adenocarcinomas (AC), squamous cell carcinomas (SCC), and
large cell carcinomas (LCC) (Travis, 2014). The TP53 gene has
been known as a tumor suppressor since the 1990s (Malkin et al.,
1990). The TP53 protein is involved in regulation of essential
cell activities, like the cell cycle, cell death, cell differentiation,
DNA repair, and formation of blood vessels (Lane and Levine,
2010), and has been called “the guardian of the genome.” These
pathways are also involved in processes required to become
a cancerous cell, and comprises several of the hallmarks of
cancer, such as sustained angiogenesis and evading apoptosis
(Hanahan and Weinberg, 2011). Since the first discovery of the
protein, much effort has been invested to reveal the spectrum
of function for this protein and the related pathways. Still,
details about the consequences of the different types of TP53
mutations for cancer patients are largely unknown. Research has
shown that mutations in the TP53 gene are frequent in almost
all types of cancers (Hollstein et al., 1991), and are present
in approximately 50% of all NSCLC (Toyooka et al., 2003).
Numerous of these mutations may be due to smoking history,
and a frequent transversion, GC to TA, is strongly correlated
to exposure to carcinogens found in tobacco (Pfeifer et al.,
2002).
Many researchers have claimed that mutations in TP53 are
prognostic, or predictive to treatment response, while others have
failed to demonstrate this association (Kandioler-Eckersberger
et al., 1999; Olivier and Taniere, 2011; Scoccianti et al., 2012).
Today, we know that a mutation in the TP53 gene can affect
the protein in many different ways. The missense mutations
are the most common type of mutations, leading to production
of protein that differs from WT TP53 by just one amino acid.
A growing body of evidence supports the claim that missense
mutant TP53 often have a gain of function (GOF), leading to
high expression levels in tumor cells (Goldstein et al., 2011).
Deletions and insertions of nucleotides are also common, which
often lead to inactive truncated protein. The TP53 WT can be
modified post-translationally in many different ways, such as
by methylation, phosphorylation, acetylation, and sumoylation
(Nguyen et al., 2014; Rodriguez, 2014), but the effect of such
modifications in vivo is difficult to assess. Altering the gene
Wrap 53, an antisense transcript of TP53, may also modulate
the TP53 activity (Mahmoudi et al., 2009), depending on
type of tissue. Thus, the difficulties in arriving at consistent
conclusions may be related to the varied functional consequences
of different mutations, leading to heterogeneous p53-related
phenotypes.
In order to explore the distribution of TP53 mutations
in lung cancer and their impact on survival in the
different histological subgroups, we have investigated TP53
mutations in 394 non-small cell lung carcinomas, and
correlated this with smoking history and clinical data, such
as survival, stage, tumor size, EGFR mutation status and
histology.
MATERIALS AND METHODS
The patients in this study were diagnosed with operable
NSCLC, and underwent curatively intended surgical resection
at Rikshospitalet, Oslo University Hospital, Norway during
the period 2006–2011. Clinical data were obtained from
questionnaires, medical journals, and histology reports, and
follow up information were reported from the patient’s local
hospital. The project was approved by the institutional review
board and the Regional Ethics Committee (S-06402b). The
participants in our study received oral and written information
and signed a written consent form before entering the
project.
Tumor tissue was dissected from the tumor periphery,
containing presumed vital tumor tissue without necrosis.
Immediately after dissection, the tumor specimens were snap
frozen in liquid nitrogen and stored at −80◦C until DNA
extraction. EDTA-blood was collected prior to surgery. Totally,
394 tumor specimens consisting of 229 AC, 112 SCC, 30
LCC, and 23 lung cancer carcinomas with other types of
histology, such as carcinoids and undifferentiated, were included
in this study. All tumor stages were present in the cohort.
However, a predominance of stages I and II was included due to
inoperable tumors in later stages. Smoking history information
revealed that 28 patients (7.1%) were never-smokers, 138 were
smokers, and 228 reported to be former-smokers, defined as
having quit smoking at least 1 year prior to diagnosis. The
never-smokers were mainly diagnosed with AC, only four
having a different histology (one SCC, one undifferentiated, two
carcinoids).
DNA Extraction
DNA was extracted from tumor tissue using Maxwell R©16 DNA
Purification Kits and a Maxwell R©16 instrument. The procedure
was performed according to technical manual, Literature #
TM2841. DNA from blood was isolated using the Master
Pure DNA purification Kit for blood according to the DNA
Purification Protocol2.
EGFR Mutation Analyses
Tumor specimens were analyzed for EGFR-mutations at Unit of
Molecular Pathology, Department of Pathology, Oslo University
Hospital. The mutation analysis of EGFR exons 18–21 was
performed by real-time PCR using TheraScreen EGFR mutation
kit (DxS, Manchester, UK), which analyses 28 of the most
commonly occurring genetic changes.
TP53 Sequencing
The gene TP53 was analyzed by the Sanger Sequencing
method in the 394 tumor samples. The procedure was
1http://www.promega.com
2http://www.epicentre.com
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performed on an Applied Biosystems 3730 DNA analyser
according to the supplier’s handbook, Applied Biosystem
3730/3730X/DNA Analysers Part 4331467 Rev.B3. All exons
from 2 to 11, including the 16 flanking base pairs of each
exon, were investigated. Information regarding primers and
PCR conditions are displayed in Supplementary Tables 1 and
2. The sequences were aligned and analyzed using SeqScape
v.2.5 according to the project template [TP53 accession nr:
NM_0005464 (TP53ref_NC000017.9_NT010718.15)]. All the
sequences were manually and independently evaluated by two
persons.
Mutation Classification
The TP53 mutations recorded in this study were classified
according to their predicted effect on the protein. The different
categories were silent, missense in non-DBM, missense in
DBM, non-sense, splice, frameshift, and inframe, as previously
described (Olivier et al., 2006). For some of the analyses, the
categories missense (non-DBM and DBM) and non-missense
(frameshift, splice, non-sense, and inframe) were used.
Next Generation Sequencing (NGS) by
Illumina Multiplexed Sequencing
Extracted DNA from 100 tumors (of the 394) and corresponding
blood samples from the same patients was sequenced using
the Agilent SureSelect Human DNA Kinome panel. This panel
includes all known kinases and kinase receptors, supplemented
with selected cancer genes. In total, protein-coding and
untranslated regions of 612 genes were sequenced. Library
construction and in solution capturing was performed following
manufacturer’s instructions. Sequencing was performed on an
Illumina Genome Analyzer generating paired-end reads of 75 bp
in length. Demultiplexing and quality filtering was performed
using Illumina’s pipeline. Downstream analysis and detection of
somatic variants was performed using an in-house developed
pipeline based on GATK (McKenna et al., 2010) and MuTect
(Cibulskis et al., 2013). Statistics for TP53 coverage are included
in Supplementary Table 3.
Statistics
Progression free survival was calculated from the time of surgery
until the time of metastasis, local recurrence, death from lung
cancer, or death from other reasons (censored). If still alive,
the last date of follow up was used (censored). Median PFS
values were estimated using Kaplan–Meyer survival analyses
and log-rank tests. Univariate and multivariate analyses with
Cox regression were used to explore the effect of different
factors on PFS. Independent covariates identified as significant
(p < 0.05) in the univariate model were evaluated in the Cox
proportional hazards model. Chi-square test (χ2) was used to
evaluate the distribution of TP53 in clinical features (IBM, SPSS,
statistics, version 21). A p-value<0.05 was considered significant.
Mutations spectrum visualization was performed in R version




Characterization and Mutation Status of
the Study Population
Of the 394 lung cancer patients analyzed for TP53 mutations,
47.2% (n = 186) harbored a TP53 mutation and 4.5% (n = 18)
had two different TP53 mutations. Twenty-nine (7.4%) patients
were diagnosed with an EGFR mutation, of which 54% were
never-smokers and 41% of these also carried a TP53 mutation in
their tumor.
Results from NGS identified six somatic mutations not
detected by Sanger sequencing. While two of these mutations
resided in the intronic region, not covered by Sanger sequencing
in this study, four were presumably missed due to low mutant
allele frequency. One deletion in a splice site and one complex
exonic mutational event (a deletion combined with either an
insertion or a substitution) found by Sanger Sequencing were
not reported as somatic by the deep sequencing pipeline.
Manual inspection of the deep sequencing data showed that
the first case was supported by 4 out of 32 reads, and the
second case by 13 out of 48 reads, at their respective locations.
In both cases, the variants were misclassified by the variant
calling software in spite of their detection by the sequencing
technology.
There was no significant difference in the tumor size or stage
between the TP53 mutated and the WT tumors. However, the
percentage of TP53 mutations increased from 44% in stage I to
60% in stage IV, and from 41% in tumor size < 2cm to 53%
in tumor size > 7cm. The frequency of TP53 mutations was
significantly differentially distributed across the histological types
(p < 0.001, χ2 test). The SCC and LCC had a higher frequency
of TP53 mutations compared to AC. The tobacco consumption
was significantly higher among those carrying a TP53 mutation
(p = 0.004, χ2 test). More clinical variables associated with TP53
mutation status are displayed in Table 1.
New Genetic Variant Identified by NGS
Three patients with the same germline variant in codon 254
(p.I254V), not previously described as a polymorphism, was
detected in approximately 50% of the reads in both tumor and
blood. All three patients carried an additional somatic mutation
in TP53. More details are listed in Supplementary Table 4.
TP53 Mutation Spectrum in Histological
Subtypes and Association with Smoking
History
In total, 128 (61%) missense mutations, 30 (14.3%) frameshift
mutations and 27 (12.9%) non-sense mutations were identified,
including double mutations. The 20.3% of the mutations in the
SCC samples were frameshift mutations, compared to 9.1% of the
mutations in the ACs (p = 0.72, χ2 test, Supplementary Table 5,
Figures 1A and 2A). The most frequently mutated sites were
codons 158 (n = 11) and 157 (n = 8) mainly being G:C > T:A
transversions (n = 7 and n = 9, respectively), and codon 179
(n = 7). Among the AC samples, four A:T > G:C transitions
were detected at codon 220, and among the SCC samples four
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TABLE 1 | Association of clinical variables to TP53 mutation status is listed below.
Characteristics of the patients All patients Patients with TP53 wt No. (%) Patients with TP53 mutation No. (%) P-value †
Sex 0.54
Male 199 102 (51) 97 (49)
Female 195 106 (54) 89 (46)
Histology <0.001
AC never smokers (AC.never) 24 15 (62.5) 9 (37.5)
AC 205 121 (59) 84 (41)
SCC 112 39 (35) 73 (65)
LCC 30 13 (43) 17 (57)
Other 23 20 (87) 3 (13)
Stage 0.55
IA/IB 222 124 (56) 98 (44)
IIA/IIB 109 53 (49) 56 (51)
IIIA/IIIB 58 29 (50) 29 (50)
IV 5 2 (40) 3 (60)
Tumor size 0.8
<2 cm 82 48 (59) 34 (41)
2–2.9 cm 124 64 (52) 60 (48)
3–4.9 cm 117 62 (53) 55 (47)
5–6.9 cm 52 25 (48) 27 (52)
>7 cm 19 9 (47) 10 (53)
Smoking history 0.004
Never-smoker 28 18 (64) 10 (36)
Cigarettes
<20 Pack years 75 52 (69) 23 (31)
20–39 Pack years 166 85 (51) 81 (49)
40–59 Pack years 94 40 (43) 54 (57)
>60 Pack years 25 9 (36) 16 (64)
Unknown 6 4(67) 2 (33)
EGFR status 0.41
EGFR mutated 29 17 (59) 12 (41)
EGFR wild type 345 175 (51) 170 (49)
Unknown 20 16 (80) 4 (20)
Frequencies are shown both in number (No.) and percent (%). †Pearson’s Chi-square test.
splice mutations in intron IVS5-1 and IVS5-2 were discovered
(Figures 1B and 2B). The G:C > T:A transversion was the
most frequent base change (n = 74, 42%), and the incidence
significantly increased proportionally with number of pack years
(p = 0.012, χ2 test). This is illustrated in Figures 1C and 2C.
Six silent mutations at codon 125 were observed, five of these
were AC.
A high frequency of double mutations was observed (n = 18,
4.6%, including the germline variant p.I254V). As depicted in
Figure 2B, the number of double mutations was distributed
equally among the different histological subtypes, and 27.8%
(n = 5) were G:C > T:A transversions. Five of the double
mutated samples were also sequenced by next generation
sequencing (NGS). The frequencies of the detected mutations are
listed in Supplementary Table 6.
In never-smokers, the proportion of G:C > T:A transversion,
was 25% (n = 2), whereas G:C > A:T transition was most
frequently observed (37.5%, n= 3). Missense mutations were the
most common type of mutation.
The Impact of TP53 Mutations on Lung
Cancer Survival
In this study, harboring a TP53 mutation did not affect PFS
significantly (HR = 1.24; 95% CI = 0.9–1.72; p = 0.19). When
stratifying into histological subgroups, patients with LCC seemed
to have an increased PFS, when a TP53 mutation was present
(HR = 0.4; 95% CI = 0.2–1.1; p = 0.08; Figure 3B). After
correction for covariates (tumor size and stage) in a multivariate
Cox Regression analysis, TP53 status was an independent
predictor of outcome in LCC patients (HR = 0.22; CI = 0.06–
0.8, p = 0.026, Supplementary Table 7). Patients with TP53
mutated AC and SCC seemed to have an unfavorable survival,
although this was not significant (Table 2 and Supplementary
Table 7). Never-smokers had a significantly reduced PFS when
carrying a TP53 mutation (HR = 5.3, 95% CI = 1.3–21.5,
p = 0.02, Figure 3A). Multivariate Cox Regression analysis
confirmed the independent prognostic value of TP53 mutations
for never-smokers (HR = 20.2; 95% CI = 2.8–143.7, p = 0.003,
Supplementary Table 7). For the different categories of TP53
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mutation, missense mutations in the DBM seem to have the
largest impact on PFS (Table 2), although not significant. Tumor
size and stage showed the strongest prognostic factor (p < 0.001,
Figures 3C,D).
DISCUSSION
In the present study, 47.2% of the lung cancers harbored a TP53
mutation. With respect to the different types of histology, the
mutation frequency was highest among patients with SCC, while
those with AC and others showed the lowest frequency. In the
LUAD study, 46% of the AC harbored a TP53 mutation and
81% were recorded with a smoking history (Cancer Genome
Atlas Research Network, 2014), which is in line with present
results. However, even if a high frequency of TP53 mutations was
observed among SCC in our study, it’s less than what was reported
in the LUSQ study (Cancer Genome Atlas Research Network,
2012), where 81% of 178 SCCs harbored a TP53 mutation. In
present study, 84% of the samples were recorded as stage I/II,
and a tendency of higher mutation rate in higher stages was seen.
The discrepancy between the two studies might be explained by
few late stage samples analyzed in present cohort. In addition, in
another study of 110 SCC a frequency of TP53 mutations on 57%
was found (Scoccianti et al., 2012), and in a meta-study of SCLC
and NSCLC, the frequency of TP53 mutations was 40% among
smokers (n = 1232), which is more in line with our findings
(Liu et al., 2014). In present study, a lower frequency of TP53
mutations was seen among patients with EGFR mutations (41%),
and among never-smokers (36%), mainly diagnosed with AC.
The frequency of TP53 mutations increased with tobacco
consumption. For the never-smokers, 36% of the patients were
TP53 mutated compared to 64% among those reported with
more than 60 pack-years. A study of somatic mutations in AC
has previously reported that smokers harbor a higher number
of mutations in genes, such as KRAS and STK11, compared to
never-smokers (Ding et al., 2008). TP53 mutations are common
in lung cancer, and occur more frequently in smokers than in
never-smokers (Sun et al., 2007). In addition, never-smokers with
TP53 WT showed beneficial PFS. This was not seen among the
smokers, who may have a lot of other mutations with impact
on the survival. A higher accumulation of mutations in genes
like NTRK2, EPHA7, PPKCG, and FLT4 in AC with higher stage
has been reported in a study of lung AC (Ding et al., 2008).
The percentage of TP53 mutations increased from 44% in stage
I to 60% in stage IV. If a higher number of stage IV samples
were present in our study, this tendency might have reached
significance. A tendency toward more TP53 mutations in the
larger tumors was also seen.
Identification of a New Variant in TP53
Germline mutations in TP53 are closely linked to the condition
called Li–Fraumeni syndrome (LFS), with an early onset of
tumorigenesis. Three patients in our cohort revealed a missense
alteration in exon 7 (p.I254V), both in tumor tissue and in
blood. According to Bougeard et al. (2008), mutation in codon
254 (p.I254L) has been reported inherited in one LFS family in
FIGURE 1 | TP53 mutations in subtypes of lung cancer. AC with no
smoking history are called “AC.never.” Double mutations and silent mutations
are included. (A) Frequency of mutation type illustrated for the different type of
histology. (B) Distribution of base change type in the histological subgroups.
(C) Distribution of base change type in groups with different smoking history.
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FIGURE 2 | TP53 mutation spectrum in subtypes of lung cancer. AC with no smoking history are called “AC.never.” Double mutations are included (A–C), and
calculated as the number of double mutations divided by the total number of mutations. Silent mutations are included (B,C). A pie chart shows the fraction of each
category. (A) Distribution of mutation type across the gene is illustrated for the different types of histology. (B) Distribution of base change types in the histological
subgroups. (C) Distribution of base change types in groups with different smoking history.
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FIGURE 3 | Kaplan–Meyer estimates of PFS for study patients by group. (A) Never-smokers without TP53 mutation showed significant prolonged time to
progression. (B) Individuals with TP53 mutated large cells carcinomas showed a beneficial PFS compared with the non-carriers. (C) Stage was significantly
associated with PFS. (D) Tumor size was significantly associated with PFS.
France, and p.I254V has been reported in six times as somatic
mutation, but is not a known polymorphism (International
Agency for Research on Cancer, 2015). Nevertheless, this variant
has been recorded in the ExAC database as a germline variant
in 1 out of 121322 alleles with a frequency of 8.24E – 06
(Lek et al., 2015). Unfortunately, phenotype information is not
available and information regarding cancer status is not known.
In a functional analysis in yeast, the predicted protein change
p.I254V was not shown to be functionally defective (Kato et al.,
2003; International Agency for Research on Cancer, 2015). In
our study, the three patients did not have an early tumor
onset, or a family history of cancer. Thus, this sequence variant
might be an un-described polymorphism, with no influence
on tumorigenesis. The mutation was present in approximately
50% of the reads in NGS, which further supports that it is a
polymorphism. However, since each of the three patients harbors
an additional somatic mutation in theTP53 gene, and the p.I254V
variant was not found among those with TP53 WT, we might
speculate that this germline missense variant may affect the
susceptibility of acquiring somatic mutations in the same gene.
If so, this might also explain why this germline variant was found
in a much higher frequency in our cohort compared to the ExAC
database. In addition, the ExAC database may contain a higher
frequency of certain disease associated variants (Lek et al., 2015).
The TP53 Mutation Spectrum Has
Different Implications in Different
Subgroups
TP53 mutation categories were un-evenly distributed in the
histological subgroups. The categories missense, frameshift,
splice, and non-sense were present in all histological subtypes.
Interestingly, a substantially higher frequency of frameshift
mutations was seen in SCC compared to AC. This did not
reach significance, which may be due to only 30 cases reported
with frameshift in total. Missense mutations (DBM and non-
DBM combined) were more frequent within the AC-group than
among SCCs and LCCs. This may indicate that TP53 mutations
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in lung cancer can have different impact for the different types
of histology, also reflected in the survival analysis. Interestingly,
the survival was significantly better for patients with LCC
harboring TP53 mutations. For patients with AC and SCC, an
opposite tendency was found. It is well known that the groups
of histology often show different clinical features, and also the
TP53 mutations may have different implications for the different
histological subtypes. In a large study of breast cancer patients,
TP53 mutations have been identified as an independent factor
of poor prognosis (Olivier et al., 2006). This may not be the
TABLE 2 | Univariate Cox regression analysis (SPSS).
Patient statistics Univariate Cox regression analysis
Variables No. of patients Events (Censored) Hazard ratio (HR) 95% CI of HR p-value
Gender 394 148 (246)
Male 199 1
Female 195 1.24 0.90–1.72 0.19
TP53 status 394 148 (246)
Wild type 208 1
Mutated 186 1.24 0.90–1.72 0.19
Histology 394 148 (246)
AC 229 1
SCC 112 0.99 0.69–1.44 0.97
LCC 30 1.4 0.83–2.41 0.21
other 23 0.29 0.09–0.93 0.037
TP53 status; AC 229 88 (141)
Wild type 136 1
Mutated 93 1.29 0.85–1.96 0.24
TP53 status; SCC 112 41 (71)
Wild type 39 1
Mutated 73 1.32 0.68–2.56 0.41
TP53 status; LCC 30 16 (14)
Wild type 13 1
Mutated 17 0.44 0.15–1.12 0.08
TP53 status; other 23 3 (19)
Wild type 20 1
Mutated 3 3.42 0.31–37.91 0.32
TP53 status; never smokers 28 9 (19)
Wild type 18 1
Mutated 10 5.3 1.32–21.5 0.02
Stage 394 148 (246)
I 222 1
II 109 0.025 0.01–0.07 < 0.001
III 58 0.04 0.02–0.11 < 0.001
IV 5 0.055 0.02–0.15 < 0.001
Tumor size 394 148 (246)
<2 cm 82 1
2–2.9 cm 124 0.19 0.10–0.37 < 0.001
3–4.9 cm 116 0.21 0.11–0.39 < 0.001
5–6.9 cm 53 0.39 0.22–0.72 < 0.002
>7 cm 19 0.23 0.12–0.48 < 0.001
EGFR status 374 143 (231)
Wild type 345 1
Mutated 29 0.78 0.41–1.49 0.46
Type of mutations 394 148 (246)
WT/silent 208 1
Missense non-DBM 48 0.89 0.57–1.38 0.6
Missense DBM 67 0.9 0.49–1.66 0.74
Non-sense/frameshift/splice 71 1.39 0.83–2.32 0.21
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case for lung cancer patients since they generally harbor a large
number of mutations due to smoking and carcinogen exposure.
Among the never-smokers who usually are recognized with fewer
mutations, a TP53 mutation was an independent prognostic
factor of poor PFS. However, the multivariate analysis contained
few individuals and must be interpreted with caution.
In this study, patients with missense mutations in the DNA
binding motif seemed to have the poorest prognosis. Poeta et al.
(2007) found that disruptive TP53 mutations were associated
with significantly decreased overall survival in head and neck
cancers. This is in contrast to a study performed on advanced
NSCLC, where having non-disruptive TP53 mutations was an
independent prognostic factor of reduced survival (Molina-Vila
et al., 2014). The SCC and LCC revealed the highest frequency
of TP53 mutations, and the number of mutations increased with
tobacco consumption. The transversion G:C > T:A, is a frequent
base change in smokers, representing 42% of the base changes
in this study. This transversion occurred equally in the different
types of histology, and did not impact survival. However, among
never-smokers the frequency was only 25%, and the G:C > A:T
transition was the most frequent base change, consistent with
other studies (Pfeifer et al., 2002; Liu et al., 2014). Interestingly,
the number of G:C > T:A transversions increased with the
number of pack years, especially after 20 pack years. We also
observed that G:C > T:A transversions tended to cluster in
hotspots, such as codons 157, 158, and 248, although not in
never-smokers. Codons 157, 158, and 248 have been registered
as smoking associated hotspot regions in lung cancer in previous
studies (Pfeifer et al., 2002; Gibbons et al., 2014). However, the
hotspots for AC were slightly different from the hotspot in SCC.
Four missense mutations in codon 220 were observed only in AC,
while an increased frequency of splice variants in IVS5-1/IVS5-2
was seen only in SCC.
CONCLUSION
The TP53 mutation profiles were different in the specific
histologies and smoking categories, with a high number of
frameshift variants in SCC. LCC with TP53 WT showed a
significantly reduced survival, with an opposite tendency for ACC
and SCC. The TP53-mutations in never-smokers differed from
that of ever smokers, supporting the claim that lung cancer in
never-smokers is a separate entity in lung cancer.
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